Skip to main content
Clinical Trials/NL-OMON39121
NL-OMON39121CompletedNot Applicable

Assessment of Comorbidities in COPD in European Symptomatic Subjects from primary care. - ACCESS

GlaxoSmithKline0 sites480 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
480

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • 1. Males/females >= 40 years of age.
  • 2. COPD (all GOLD-stages) diagnosed >= 12 months ago.
  • 3. FEV1/FVC (tiffeneau-index) after use of bronchodilator < 0.70.
  • 4. Smoking history of >= 10 packyears
  • 5. Singed informed consent form.

Exclusion Criteria

  • 1.In the opinion of the investigator, there is a current primary diagnosis of asthma (patients with a primary diagnosis of COPD but who also have asthma may be included)
  • 2.A diagnosis of fibrosis or asbestosis
  • 3.Diagnosis of cancer - includes current and within the last 5 years (patients in remission for >= 5 years may be included). Patients diagnosed with cancer during the study will be withdrawn
  • 4.Diagnosis of clinically significant bronchiectasis
  • 5.Subjects who are concurrently participating in any clinical study or who have received any investigational drugs within 4 weeks of Visit 1, or who will start any during the study period.
  • 6.Unable to or unwilling to conform with the study requirements including completion of the health status questionnaires
  • 7.Females who are pregnant or lactating.

Investigators

Similar Trials